Navigating Centene Wegovy Prior Authorization for Weight Management

Wegovy: Indication and Prior Authorization Triggers

Wegovy, manufactured by Novo Nordisk, is a GLP-1 receptor agonist indicated for chronic weight management. Due to its cost and specific clinical guidelines, prior authorization is almost universally required. Common reasons for Centene subsidiaries to require PA for Wegovy include verifying specific BMI thresholds, confirming completion of prior lifestyle and nutrition programs, and assessing for benefit exclusions related to weight loss medications.

Centene's Decentralized Structure and Wegovy PA

Centene Corporation operates as a federation of state-licensed subsidiaries, such as Fidelis Care in New York, Health Net in California, Meridian in Michigan, and Sunshine Health in Florida. This structure means that prior authorization policies for Wegovy, including formulary placement and specific criteria, can vary materially by individual subsidiary and by plan type (e.g., Medicaid, Ambetter ACA marketplace, Wellcare/Allwell Medicare Advantage). There is no single 'Centene medical policy library' for providers to reference; policies are published at the subsidiary level.

Key Criteria for Centene Wegovy Prior Authorization

• **BMI Thresholds:** Documentation of a specific Body Mass Index (BMI) that meets the plan's medical necessity guidelines.
• **Prior Lifestyle Program:** Verification of patient participation in and failure of a supervised diet and exercise program.
• **Benefit Exclusion:** Assessment of whether weight loss medications are a covered benefit under the specific plan, as some benefit designs may exclude them.
• **Medical Necessity Review:** Evaluation against clinical criteria, which may include InterQual criteria for medical benefit services or state Medicaid agency rules for Medicaid lines.
• **Step Therapy Requirements:** Adherence to any formulary-driven step therapy protocols requiring trial and failure of alternative medications.
• **Quantity Limits:** Compliance with any prescribed maximum dosage or duration of therapy.

Centene Wegovy PA Submission Channels

For Wegovy, which can be covered under either the medical or pharmacy benefit, submission channels vary. Pharmacy benefit prior authorizations typically route through Envolve Pharmacy Solutions, Centene's in-house pharmacy services entity, and are accessible via industry ePA platforms like CoverMyMeds and Surescripts. Medical benefit prior authorizations are submitted through the specific Centene subsidiary's provider portal or via X12 278 transactions through a clearinghouse. Ambetter and Wellcare plans utilize the same subsidiary portals but follow their distinct PA criteria.

Centene PA Decision Timeframes: Impact of Plan Type and Regulations

Prior authorization turnaround times for Wegovy with Centene plans are not uniform. Medicaid managed-care lines are governed by state Medicaid agency rules, which vary significantly by state. Wellcare and Allwell Medicare Advantage plans adhere to CMS-mandated organization determination timeframes (14 calendar days for standard requests, 72 hours for expedited requests). Ambetter ACA marketplace plans follow applicable QHP-on-FFM rules and state insurance regulations. Notably, Centene's broad scope as an 'impacted payer' under CMS-0057-F means many of its lines will transition to 72-hour standard and 24-hour expedited PA decision timeframes on a phased compliance timeline.

Navigating Centene Wegovy Denials and Appeals

• **Common Denial Reasons:** Denials for Wegovy often stem from insufficient documentation of medical necessity, failure to meet BMI or lifestyle program criteria, or the medication being a benefit exclusion.
• **Denial Communication:** Denials are typically communicated via X12 277/835 transactions or through status updates on the subsidiary's provider portal.
• **Subsidiary-Specific Appeals:** The appeal pathway is unique to each Centene subsidiary.
• **Medicaid Appeals:** For Medicaid managed-care plans, appeals follow the state Medicaid agency's mandated appeal and grievance structure, which includes state fair-hearing rights.
• **Medicare Advantage Appeals:** Wellcare and Allwell Medicare Advantage lines follow the CMS-mandated 5-level appeal structure for organization determinations.